AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 154 min read$PURENeutralMed

PURE BIOSCIENCE, INC. (PURE): Results of Operations and Financial Condition

PURE BIOSCIENCE, INC. (PURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results EL CAJON, Calif. – PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobia

AI DeskJune 15, 2026
AI analysis
Relevance
7/10
Novelty
8/10
Actionability
Med
Sentiment · $PURE
Neutral
Timing
filed June 15, 2026 (after market)
Market alignment
Losses persist but sales increased and management succession is defined, supporting a mixed read (cautious optimism).
Why this matters for $PURE

Quarterly financials and leadership transition (CEO retirement July 31, 2026; Jeff Kitchell as CEO Aug 1) create near-term sentiment and execution risk/opportunity.

Relevance context

PURE reported fiscal Q3 ended April 30, 2026 results, including net product sales of $506k and a net loss of $624k, plus CEO succession.

Price-impact prediction

Likely modest volatility around microcap liquidity as traders digest losses, sales growth, and management change; direction depends on whether investors view PURE Clean adoption and cost reductions as durable.

Background

This is a Form 8-K (Item 2.02) with Exhibit 99.1 reporting PURE Bioscience’s fiscal third-quarter results and providing business/management updates.

Why it matters

Traders can reassess near-term fundamentals using the disclosed quarterly and year-to-date sales/loss figures, and reprice governance/execution risk ahead of the CEO handoff on Aug 1, 2026.

Market relevance

Primary-source financials plus a defined CEO transition date can drive microcap sentiment and positioning, even without explicit guidance.

Market effects

Sector

Microcap antimicrobial/food-safety platform companies may see read-across interest if PURE Clean adoption and distribution penetration are viewed as validating the SDC platform.

Regional

Limited; company is US-based and updates are company-specific.

Global

Low; no international regulatory or supply-chain shocks disclosed.

Alternative perspectives

Contrarian view

Sales growth is small in absolute terms ($506k vs $489k), while losses remain sizable, so the market may discount the adoption narrative until revenue scales materially.

Overlooked factors

Investors may focus more on the CEO transition mechanics and board changes than on the quarterly P&L, especially in a thinly traded OTCQB name.

Key entities

  • company
    PURE Bioscience, Inc.

    OTCQB-listed antimicrobial technology company reporting fiscal Q3 results and CEO succession.

  • person
    Robert Bartlett

    Announced plans to retire as CEO effective July 31, 2026; remains Board Member and Advisor.

  • person
    Jeff Kitchell

    Appointed to take over as CEO effective August 1, 2026; also becomes Board Member.

  • person
    Bernard Blotner

    Leaving PURE’s Board of Directors.

Read at source← All news

Related articles

JUN 6
$PUREMedAI 8/10

Purecore Metals Inc.: Purecore Announces up to $1.5 Million Non-Brokered Private Placement

Purecore Metals Inc. (CSE: PURE; FSE: J8Y) announced a non-brokered private placement of up to 1,500,000 units at $1.00 per unit for gross proceeds of up to $1.5 million. Each unit includes a common share and a warrant to buy another share at $2.00 for three years, with potential early expiry. Proceeds will fund mineral property acquisition, working capital and general purposes, and the company clarified its May 15 options grant.

finanznachrichten.de4 min
JUN 6
$PUREMedAI 8/10

Purecore Announces up to $1.5 Million Non-Brokered Private Placement

Purecore Metals Inc. (CSE: PURE; FSE: J8Y) announced a non-brokered private placement of up to 1,500,000 units at $1.00 per unit for gross proceeds up to $1.5 million. Each unit includes a common share and a warrant exercisable at $2.00 for three years, with possible early expiry. Proceeds are earmarked for mineral property acquisition, working capital, and corporate/marketing uses. The company also clarified its May 15, 2026 option grant.

manilatimes.net4 min
JUL 10
$ARTWMed

ARTS WAY MANUFACTURING CO INC (ARTW): Results of Operations and Financial Condition

ARTS WAY MANUFACTURING CO INC (ARTW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_986102.htm EXHIBIT 99.1 ex_986102.htm Exhibit 99.1 FOR IMMEDIATE RELEASE July 9, 2026 ART ’ S WAY REPORTS 26% INCREASE IN FIRST HALF SALES AND 20% GROWTH IN OPERATING INCOME ARMSTRONG, IOWA, July 9, 2026 – Art’s-Way Manufacturing Co., Inc. (Nasdaq: ARTW) (the “Compan

SEC EDGAR 8-K4 min
JUL 10
$SEVMed

Aptera Motors Announces a Warrant Inducement Transaction for $5.7 Million in Gross Proceeds

Aptera Motors (NASDAQ: SEV) said it exercised existing March 2026 warrants to buy up to 2,775,000 shares of Class B common stock at $2.07 per share, raising about $5.7 million gross. In return, it will issue new unregistered warrants for up to 4,162,500 shares at $2.25, exercisable after six months, expiring in 5.5 years. Closing expected around July 13, 2026; proceeds for working capital and vehicle validation.

manilatimes.net4 min
JUL 10
Med

SK Hynix Targets $26.5 Billion ADR Sale as AI Demand Surges

SK Hynix, according to GuruFocus, plans a U.S. ADR offering expected to raise about $26.5 billion, selling 177.9 million ADRs. Orders reportedly exceeded the offer size by more than 7x. The article notes SK Hynix shares have risen about 700% in a year and compares performance with Micron. It also mentions Kioxia and TSM ADRs.

yahoo.com4 min